Blockade of PD-1/PD-L1 promotes adoptive T-Cell immunotherapy in a tolerogenic environment

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Blake, Stephen J P ^a   Ching, Alan L H ^a   Kenna, Tony J ^a   Galea, Ryan ^a   Large, Justin ^a   Yagita, Hideo ^b   Steptoe, Raymond J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; CD274 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INTERACTION; CELL TRANSPORT; CELLULAR IMMUNITY; CHRONIC DISEASE; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOID TISSUE; MALE; MEMORY T LYMPHOCYTE; MOUSE; MOUSE MODEL; NONHUMAN; VIRUS INFECTION; ANIMAL; C57BL MOUSE; IMMUNOLOGY; T LYMPHOCYTE;

MUS;

ANIMALS; ANTIGENS, CD274; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84924090823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119483     Document Type: Article

References (61)

1. Wolint P, Betts MR, Koup RA, Oxenius A. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J Exp Med. 2004; 199: 92-936. doi: 10.1084/jem. 20031799
2. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102: 9571-9576. doi: 10.1073/pnas.0503726102 PMID: 15980149
3. Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012; 35: 651-660. doi: 10.1097/CJI. 0b013e31827806e6 PMID: 23090074
4. Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, et al. The stoichiometric production of IL-2 and IFN-? mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med. 2012, doi: 10.1126/scitranslmed.3004306
5. Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, et al. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother. 2011; 60: 739-746. doi: 10.1007/s00262-011-0977-7 PMID: 21305379
6. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12: 269-281. doi: 10.1038/nri3191 PMID: 22437939
7. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23: 2346-2357. doi: 10.1200/JCO.2005.00. 240 PMID: 15800326
8. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004; 64: 2865-2873. doi: 10.1158/0008-5472.CAN-03-3066 PMID: 15087405
9. Yang C, Robbins PD. The Roles of Tumor-Derived Exosomes in Cancer Pathogenesis. Clin Dev Immunol. 2011; 2011: 842849. doi: 10.1155/2011/842849 PMID: 22190973
10. McDonnell AM, Robinson BWS, Currie AJ. Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins? Clin Dev Immunol. 2010; 2010:539519. doi: 10.1155/2010/539519 PMID: 20976125
11. Kenna TJ, Thomas R, Steptoe RJ. Steady-state dendritic cells expressing cognate antigen terminate memory CD8+ T-cell responses. Blood. 2008; 111: 2091-2100. doi: 10.1182/blood-2007-07-103200 PMID: 18003887
12. Kenna TJ, Waldie T, McNally A, Thomson M, Yagita H, Thomas R, et al. Targeting antigen to diverse APCs inactivates memory CD8+ T cells without eliciting tissue-destructive effector function. Journal of Immunology. 2010; 184: 598-606. doi: 10.4049/jimmunol.0900032 PMID: 19995901
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012; 12: 252-264. doi: 10.1038/nrc3239 PMID: 22437870
14. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007; 8: 239-245. doi: 10.1038/ni1443 PMID: 17304234
15. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26: 677-704. doi: 10.1146/annurev.immunol.26.021607.090331 PMID: 18173375
16. Barber DL, Wherry EJ, Masupost D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8+ T cells during chronic viral infection. Nature. 2006; 439: 682-687. doi: 10.1038/ nature04444 PMID: 16382236
17. Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood. 2007; 110: 180-185. doi: 10.1182/blood-2006-11-060087 PMID: 17289811
18. Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007; 110: 186-192. doi: 10.1182/blood-2006-12-062422 PMID: 17392506
19. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004; 64: 1140-1145. doi: 10.1158/0008-5472.CAN-03-3259 PMID: 14871849
20. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PDL1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-2465. doi: 10.1056/ NEJMoa1200694 PMID: 22658128
21. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454. doi: 10.1056/ NEJMoa1200690 PMID: 22658127
22. Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y, Yagita H, et al. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol. 2010; 185: 5082-5092. doi: 10.4049/jimmunol.1001821 PMID: 20926790
23. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013; 14: 1212-1218. doi: 10.1038/ni.2762 PMID: 24240160
24. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003; 198: 63-69. doi: 10.1084/jem.20022125 PMID: 12847137
25. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol. 2005; 6: 280-286. doi: 10.1038/ni1165 PMID: 15685176
26. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712. doi: 10.1038/44385 PMID: 10537110
27. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med. 2001; 194: 953-966. doi: 10.1084/jem.194.7.953 PMID: 11581317
28. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell. 1994; 76: 17-27. doi: 10.1016/0092-8674(94)90169-4 PMID: 8287475
29. Steptoe RJ, Ritchie JM, Wilson NS, Villadangos JA, Lew AM, Harrison LC. Cognate CD4+ help elicited by resting dendritic cells does not impair the induction of peripheral tolerance in CD8+ T cells. JI. 2007; 178: 2094-2103. doi: 10.4049/jimmunol.178.4.2094 PMID: 17277113
30. Fiorenza S, Kenna TJ, Comerford I, McColl S, Steptoe RJ, Leggatt GR, et al. A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin. J Immunol 2012; 189: 5622-5631. PMID: 23144496
31. Agata A, Kawasaki Y, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996.; 8: 765-772. doi: 10. 1093/intimm/8.5.765 PMID: 8671665
32. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003; 33: 3117-3126. doi: 10.1002/eji.200324270 PMID: 14579280
33. Takamura S, Tsuji-Kawahara S, Yagita H, Akiba H, Sakamoto M, Chikaishi T, et al. Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol. 2010; 184: 4696-4707. doi: 10.4049/jimmunol.0903478 PMID: 20351188
34. Huang CT, Huso DL, Lu Z, Wang T, Zhou G, Kennedy EP, et al. CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol. 2003; 170: 3945-3953. doi: 10. 4049/jimmunol.170.8.3945 PMID: 12682221
35. Hernandez J, Aung S, Redmond WL, Sherman LA. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med. 2001; 194: 707-717. doi: 10.1084/jem.194.6.707 PMID: 11560988
36. Huang X, Yang Y. Transient gain of effector function by CD8+ T cells undergoing peripheral tolerance to high-dose self-antigen. Eur J Immunol. 2004; 34: 1351-1360. doi: 10.1002/eji.200324734 PMID: 15114668
37. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27 (1):111-22: 111-122. doi: 10.1016/j.immuni.2007.05.016 PMID: 17629517
38. Xu D, Fu HH, Obar JJ, Park JJ, Tamada K, Yagita H, et al. A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection. PLoS One. 2013; 8: e56539. doi: 10.1371/journal.pone.0056539 PMID: 23409193
39. Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010; 116: 1291-1298. doi: 10.1182/blood-2010-01-265975 PMID: 20472828
40. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004; 101: 10691-10696. doi: 10.1073/pnas.0307252101 PMID: 15249675
41. Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011; 187: 1097-1105. doi: 10.4049/jimmunol.1003496 PMID: 21697456
42. Kuipers H, Muskens F, Willart M, Hijdra D, van Assema FB, Coyle AJ, et al. Contribution of the PD-1 ligands/ PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol. 2006; 36: 2472-2482. doi: 10.1002/eji.200635978 PMID: 16917960
43. Mueller SN, Matloubian M, Clemens DM, Sharpe AH, Freeman GJ, Gangappa S, et al. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A. 2007; 104: 15430-15435. doi: 10.1073/pnas.0702579104 PMID: 17878315
44. Mühlbauer M, Fleck M, Schütz C, Weiss T, Froh M, Blank C, et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and-gamma and mediates T cell apoptosis. J Hepatol. 2006; 45: 520-528. doi: 10.1016/j.jhep.2006.05.007 PMID: 16876901
45. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006; 580: 755-762. doi: 10.1016/j.febslet.2005.12.093 PMID: 16413538
46. Benedict CA, Loewendorf A, Garcia Z, Blazar BR, Janssen EM. Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J Immunol. 2008; 180: 4836-4847. doi: 10.4049/jimmunol.180.7.4836 PMID: 18354207
47. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009; 10: 29-37. doi: 10.1038/ni.1679 PMID: 19043418
48. Probst HC, Lagnel J, Kollias G, van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity. 2003; 18: 713-720. doi: 10.1016/S1074-7613(03)00120-1 PMID: 12753747
49. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5: 263-274. doi: 10.1038/nrc1586 PMID: 15776005
50. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207: 2187-2194. doi: 10.1084/jem.20100643 PMID: 20819927
51. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107: 4275-4280. doi: 10.1073/pnas.0915174107 PMID: 20160101
52. Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, et al. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Research. 2013; 73: 605-616. doi: 10.1158/0008-5472.CAN-12-2179 PMID: 23188506
53. Pilon-Thomas S, Mackay A, Vohra N, J.J. M. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol. 2010; 184: 3442-3449. doi: 10.4049/jimmunol.0904114 PMID: 20194714
54. Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, et al. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol. 2009; 183: 7898-7908. doi: 10. 4049/jimmunol.0901060 PMID: 20007574
55. Sierro SR, Donda A, Perret R, Guillaume P, Yagita H, Levy F, et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol. 2011; 41: 221-2228. doi: 10.1002/eji.201041235
56. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-? inducible chemokines. Cancer Research. 2012; 72: 5209-5218. doi: 10.1158/0008-5472.CAN-12-1187 PMID: 22915761
57. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124: 687-695. doi: 10.1172/JCI67313 PMID: 24382348
58. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010; 116: 2484-2493. doi: 10.1182/blood-2010-03-275446 PMID: 20570856
59. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013; 19(20):. 5636-5646. doi: 10.1158/1078-0432.CCR-13-0458 PMID: 23873688
60. Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, et al. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol. 2009; 182: 2102-2112. doi: 10.4049/jimmunol.0802769 PMID: 19201863
61. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723. doi: 10.1056/ NEJMoa1003466 PMID: 20525992